Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Hematol. 2002 Jan;39(1):32-40.

Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation.

Author information

  • 1Laboratoire de Thérapie Cellulaire et Génique, INSERM U429, Hôpital Necker-Enfants Malades, Paris, France.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for many hematologic malignancies or inherited disorders. Ex vivo T-cell depletion (TCD) of the graft and post-transplantation immunosuppression efficiently prevent the development of graft-versus-host disease (GVHD). However, the consequence of these nonspecific approaches is a long-lasting immunodeficiency associated with increased disease relapse, graft rejection, and reactivation of viral infections. Donor lymphocyte infusion, to treat leukemic relapse after allogeneic HSCT, can cause severe GVHD. Several strategies are being optimized to specifically inactivate anti-host T cells while preserving antileukemic or antimicrobial immunocompetence, based on ex vivo or in vivo elimination of anti-host T cells or on the modulation of their anti-host activity.

Copyright 2002 by W.B. Saunders Company.

PMID:
11799527
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk